PDF(Pubmed)
Abstract：
Currently, stem cells are a prominent focus of regenerative engineering research. However, due to the limitations of commonly used stem cell sources, their application in therapy is often restricted to the experimental stage and constrained by ethical considerations. In contrast, urine-derived stem cells (USCs) offer promising advantages for clinical trials and applications. The noninvasive nature of the collection process allows for repeated retrieval within a short period, making it a more feasible option. Moreover, studies have shown that USCs have a protective effect on organs, promoting vascular regeneration, inhibiting oxidative stress, and reducing inflammation in various acute and chronic organ dysfunctions. The application of USCs has also been enhanced by advancements in biomaterials technology, enabling better targeting and controlled release capabilities. This review aims to summarize the current state of research on USCs, providing insights for future applications in basic and clinical settings.
摘要：
目前,干细胞是再生工程研究的重点。然而,由于常用干细胞来源的限制，它们在治疗中的应用通常仅限于实验阶段，并受到伦理考虑的限制。相比之下,尿液来源的干细胞（USCs）为临床试验和应用提供了有希望的优势。收集过程的非侵入性允许在短时间内重复检索，使其成为更可行的选择。此外，研究表明，USCs对器官有保护作用，促进血管再生，抑制氧化应激，减少各种急性和慢性器官功能障碍的炎症。生物材料技术的进步也增强了USC的应用，实现更好的靶向和控制释放能力。这篇综述旨在总结USCs的研究现状，为基础和临床环境中的未来应用提供见解。
